NORTHVALE, N.J. & BARRIE, ONTARIO, April 17 /CNW/ - Ivivi Technologies,
Inc. (AMEX: II), a developer of non-invasive, electrotherapeutic technologies,
today announced that Barrie, Ontario-based T.H.E. Medical, Ivivi's exclusive
Canadian distributor, has obtained approval from Health Canada, Canada's
Federal regulatory department for health matters, for the distribution of
Ivivi's Roma3 pulsed electromagnetic field (PEMF) therapy device in Canada.
Roma3 represents Ivivi's latest technological advancement in
Electroceuticals(TM) and will now be available in Canada for the non-invasive
treatment of pain and edema in wounds.
"We believe the market for wound care products in Canada, like the rest
of the world, will continue to grow, driven by an aging population as well as
the rise in the incidence of diabetes. We are delighted that healthcare
providers and patients in Canada will now be able to benefit from the Roma3,"
said Andre' DiMino, Vice Chairman and Co-Chief Executive Officer of Ivivi.
"Our PEMF technology has been safely used in over 600,000 treatments since the
mid 1990's to non-invasively treat injured soft tissue pain and swelling by
stimulating biochemical and physiological processes."
"We are very excited to bring this next generation wound care technology
to Canada. The Roma3 has shown excellent clinical outcomes while drastically
lowering the cost-per-treatment when compared to other technologies currently
available," said Noel Duquette, Co-Chair of T.H.E. Medical.
"We were drawn to T.H.E. Medical because of their fine reputation and
ability to educate, sell and support the platform across the country," added
"T.H.E Medical has demonstrated both the vision and capacity to bring our
technology to a large clinical population," said David Saloff, President and
Co-CEO of Ivivi. "We believe this is an excellent opportunity to make a
difference in the lives of many Canadians, without many of the risks
associated with other therapies."
The Roma3 is primarily marketed as a rental product to the chronic care
markets, particularly for use in long-term acute care hospitals, as well as in
long-term care nursing facilities, rehabilitation hospitals, acute care
hospitals and facilities and home health systems.
About Ivivi Technologies, Inc.
Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology
company focusing on designing, developing and commercializing its proprietary
electrotherapeutic technology platform. Ivivi's research and development
activities are focused specifically on pulsed electromagnetic field, or PEMF,
technology, which, by creating a therapeutic electrical current in injured
soft tissue, stimulates biochemical and physiological processes to help repair
injured tissue and reduce related pain and inflammation. The Company's
Electroceuticals(TM) have been used in non-invasive treatments for a wide
array of conditions, including pain and edema in chronic wounds, plastic and
reconstructive surgery and chronic inflammatory disorders. For more
information visit www.ivivitechnologies.com.
About T.H.E. Medical
Based in Barrie-Ontario, T.H.E. Medical, established in 1989, is the
leading Canadian manufacturer of high-quality, full-line institutional patient
care and patient handling products. For more information visit
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance or events.
Although management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such expectations will
prove to be correct and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties,
including, but not limited to, the Company's limited operating history,
history of significant and continued operating losses and substantial
accumulated earnings deficit, difficulties with its financial accounting
controls, the failure of the market for the Company's products to continue to
develop, the inability for customers to receive third party reimbursement, the
inability to obtain additional capital, the inability to protect the Company's
intellectual property, the loss of any executive officers or key personnel or
consultants, competition, changes in the regulatory landscape or the
imposition of regulations that affect the Company's products and other risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission, including the Company's registration statement on Form
SB-2. The Company assumes no obligation to update the information contained in
this press release.
For further information:
For further information: Public Relations: Avalanche Strategic
Communications Denyse Dabrowski, 201-488-0049 Mobile: 201-916-7122
firstname.lastname@example.org or Cameron Associates Investors: Alison Ziegler,
212-554-5469 or Financial Media: Deanne Eagle, 212-554-5463